OncoSec Medical (NASDAQ:ONCS) Downgraded by Zacks Investment Research to Sell

Zacks Investment Research cut shares of OncoSec Medical (NASDAQ:ONCSGet Rating) from a hold rating to a sell rating in a report released on Tuesday morning, Zacks.com reports.

According to Zacks, “OncoSec Medical Incorporated is a biomedical company engaged in the designing, development and commercialization of therapeutic oncology products. It also develops novel OMS ElectroOncology therapies and OncoSec Medical System for the treatment of solid tumors. OncoSec Medical Incorporated is based in San Diego, California. “

ONCS has been the subject of a number of other research reports. BTIG Research dropped their target price on shares of OncoSec Medical from $10.00 to $5.00 and set a buy rating for the company in a research report on Wednesday, March 16th. StockNews.com assumed coverage on shares of OncoSec Medical in a research report on Monday. They set a sell rating for the company.

NASDAQ ONCS opened at $1.06 on Tuesday. OncoSec Medical has a 12 month low of $0.75 and a 12 month high of $5.34. The company has a 50-day moving average of $1.02 and a 200-day moving average of $1.26. The company has a market cap of $41.71 million, a P/E ratio of -1.02 and a beta of 1.99.

OncoSec Medical (NASDAQ:ONCSGet Rating) last posted its quarterly earnings data on Tuesday, March 15th. The biotechnology company reported ($0.25) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.14). On average, analysts expect that OncoSec Medical will post -0.59 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. HighTower Advisors LLC purchased a new position in OncoSec Medical in the 3rd quarter worth approximately $45,000. Two Sigma Advisers LP boosted its holdings in OncoSec Medical by 128.2% in the 3rd quarter. Two Sigma Advisers LP now owns 361,401 shares of the biotechnology company’s stock worth $770,000 after acquiring an additional 203,010 shares during the period. Susquehanna International Group LLP boosted its holdings in OncoSec Medical by 62.7% in the 4th quarter. Susquehanna International Group LLP now owns 44,075 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 16,990 shares during the period. Long Focus Capital Management LLC purchased a new position in OncoSec Medical in the 4th quarter worth approximately $66,000. Finally, Geode Capital Management LLC boosted its holdings in OncoSec Medical by 7.1% in the 4th quarter. Geode Capital Management LLC now owns 262,478 shares of the biotechnology company’s stock worth $251,000 after acquiring an additional 17,467 shares during the period. Hedge funds and other institutional investors own 16.39% of the company’s stock.

OncoSec Medical Company Profile (Get Rating)

OncoSec Medical, Inc is a biotechnology company focused on designing, developing and commercializing therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, uses an electroporation device, with the aim of reversing the immunosuppressive microenvironment in the treated tumor.

Recommended Stories

Get a free copy of the Zacks research report on OncoSec Medical (ONCS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.